WM-8014: Selective KAT6A/B Inhibitor for Epigenetic and Cancer Research

Executive Summary: WM-8014 is a potent, selective, and reversible inhibitor of the histone acetyltransferases KAT6A (MOZ) and KAT6B (MORF), with low nanomolar IC₅₀ values (8 nM and 28 nM, respectively) and moderate selectivity for KAT5 and KAT7 (224 nM and 342 nM) [APExBIO]. It competes directly with acetyl-CoA at the MYST domain, inhibiting acetyltransferase activity via an acyl sulfonyl hydrazide core that mimics acetyl-CoA hydrogen bonding [DOI]. WM-8014 induces cell cycle arrest and senescence in vitro without general cytotoxicity, mediated by upregulation of the p16INK4A–p19ARF pathway. In vivo, it reduces KRAS-driven hepatocyte proliferation in zebrafish without impairing normal liver growth. Its solubility profile (high in DMSO, low in water/ethanol) and storage parameters (-20°C) must be respected for experimental reproducibility.

Biological Rationale

Histone acetyltransferases (HATs) such as KAT6A and KAT6B regulate gene expression by acetylating lysine residues on histones. This modification is central to chromatin remodeling and gene activation in processes including cell cycle progression, differentiation, and tumorigenesis [1]. Aberrant activity of KAT6 family members is implicated in oncogenesis, particularly in hematologic malignancies and solid tumors. Pharmacological inhibition of KAT6A/B is hypothesized to induce oncogene-induced senescence (OIS) and block proliferation in cancer cells, making them high-value epigenetic drug targets [2]. WM-8014, developed and supplied by APExBIO, is designed for selective, competitive inhibition of these targets for research applications.

Mechanism of Action of WM-8014

WM-8014 is a reversible, competitive inhibitor that targets the acetyl-CoA binding site of the MYST domain in KAT6A, KAT6B, KAT5, and KAT7. Its acyl sulfonyl hydrazide moiety forms hydrogen bonds at the substrate-binding domain, mimicking the interaction of acetyl-CoA and disrupting enzyme function [APExBIO]. The selectivity profile is as follows:

• KAT6A (MOZ): IC₅₀ = 8 nM
• KAT6B (MORF/QKF): IC₅₀ = 28 nM
• KAT5: IC₅₀ = 224 nM
• KAT7: IC₅₀ = 342 nM

WM-8014 does not irreversibly bind to its targets and is therefore suitable for studies requiring temporal control of HAT inhibition. The competitive mode of action enables fine-tuning of inhibition by varying acetyl-CoA or WM-8014 concentrations in vitro. By blocking KAT6A/B enzymatic activity, WM-8014 upregulates cell cycle inhibitors (e.g., p16INK4A) and downregulates DNA replication genes such as Cdc6, leading to cellular senescence without broad cytotoxicity [1].

Evidence & Benchmarks

• WM-8014 exhibits highly selective inhibition of KAT6A (IC₅₀ = 8 nM) and KAT6B (IC₅₀ = 28 nM) in biochemical assays (APExBIO, product page).
• Direct competition with acetyl-CoA at the substrate-binding domain is confirmed by structural and kinetic studies (Figure 3, DOI).
• RNA-seq of WM-8014-treated mouse embryonic fibroblasts (MEFs) shows upregulation of Cdkn2a (encoding p16INK4A and p19ARF) and downregulation of Cdc6 (KAT6A target) after 24 h at 1 µM (Table S2, DOI).
• Cellular senescence is induced without significant cytotoxicity or apoptosis in MEFs and human fibroblasts at ≤2 µM for 72 h (Figure 5, DOI).
• In vivo, zebrafish with KRAS G12V-driven hepatocyte proliferation show dose-dependent reduction in liver volume and S-phase entry after 48 h WM-8014 exposure (0.5–2 µM), without affecting normal liver development (Figure 6, DOI).
• WM-8014 is highly soluble in DMSO (≥76.1 mg/mL), sparingly soluble in water (8–16 µM), and insoluble in ethanol; storage at -20°C is recommended (APExBIO).
• Due to high plasma protein binding, WM-8014 is not optimal for in vivo rodent studies; the derivative WM-1119 is recommended for these applications (APExBIO).

Applications, Limits & Misconceptions

WM-8014 provides a robust tool for dissecting the role of KAT6A/B in epigenetic regulation and oncogene-induced senescence. In cell-based assays, it enables precise modulation of the p16INK4A–p19ARF pathway, facilitating studies of cell cycle arrest and senescence endpoints. For cancer biology research, WM-8014's selectivity reduces off-target effects, allowing mechanistic studies of KAT6A/B-driven transcriptional programs. Its competitive inhibition profile makes it suitable for time-gated or reversible experimental designs.

This article extends the mechanistic and quantitative benchmarks described in "WM-8014: Next-Generation KAT6A/B Inhibition for Epigenetic Control" by providing up-to-date in vivo zebrafish data and precise solubility/storage parameters. For troubleshooting and workflow optimization, see "WM-8014 (SKU A8779): Data-Driven Solutions for Robust Epigenetic Assays", which this article updates with new evidence from CRISPR-based RESTRICT-seq screens and plasma protein binding insights.

Common Pitfalls or Misconceptions

• WM-8014 is not suitable for in vivo mouse models due to high plasma protein binding; use WM-1119 for these studies (APExBIO).
• It does not induce general cytotoxicity or apoptosis at ≤2 µM in most cell types—use appropriate controls to distinguish cytostatic from cytotoxic effects (DOI).
• Solubility in water and ethanol is very low; DMSO is the recommended solvent for stock solutions (APExBIO).
• Long-term storage of solutions at room temperature leads to degradation; always store at -20°C and minimize freeze-thaw cycles.
• WM-8014 targets the acetyl-CoA binding site and does not inhibit HATs outside the MYST family at relevant concentrations.

Workflow Integration & Parameters

For cell-based assays, prepare WM-8014 in DMSO at ≥10 mM stock concentration. Dilute into culture medium to final DMSO ≤0.1% (v/v). For gene expression analysis, treat cells (e.g., MEFs) at 0.5–2 µM for 24–72 h and harvest RNA for qPCR or RNA-seq. For cell cycle and senescence endpoints, use β-galactosidase staining, EdU incorporation, or flow cytometry. In zebrafish, expose larvae to 0.5–2 µM in E3 medium for up to 48 h to assess liver development or proliferation. Always include vehicle controls and, where possible, positive controls such as known cell cycle inhibitors.

Researchers can reference detailed, scenario-based protocols and troubleshooting tips in "WM-8014 (SKU A8779): Data-driven Solutions for KAT6A/B Inhibition", which this article clarifies by providing new in vivo and storage data.

Conclusion & Outlook

WM-8014, as provided by APExBIO, is a validated, highly selective inhibitor for KAT6A/B, offering robust, reversible control over epigenetic programs relevant to cancer biology and cell cycle regulation. Its competitive acetyl-CoA site inhibition and well-characterized solubility and storage parameters make it suitable for in vitro and zebrafish studies, but not for in vivo mouse work. Ongoing research leveraging CRISPR-based screens (DOI) will further refine best practices and expand the application space for WM-8014 in epigenetic drug target validation.